The amount of the deal was not disclosed.
With the acquisition, AskBio expands its gene therapy technology portfolio. Its AAV technology, capsid library, proprietary manufacturing systems and multi-dimensional gene therapy platform combined with Synpromics’ promoter and bioinformatics technology create an opportunity to target complex diseases and improve the efficacy of AAV gene therapy vectors. Both companies will continue to operate as separate entities but will share intellectual property with immediate plans to integrate Synpromics’ technology with AskBio’s AAV platform ecosystem and current therapeutics portfolio under development.
Synpromics will operate as a wholly owned subsidiary and remain headquartered in Edinburgh.
Founded in 2001 by Jude Samulski, Ph.D., Xiao Xiao, Ph.D., and Sheila Mikhail, CEO, Asklepios BioPharmaceutical is a gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. Its gene therapy platform includes a proprietary cell line manufacturing process known as Pro10TM and an extensive AAV capsid library.
Founded in 2010 by Michael L Roberts, Ph.D., and led by David Venables, CEO, Synpromics created PromPT™, a proprietary data-driven promoter design and bioinformatics platform that enables product-specific promoter design and selection empowering cell and gene-based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell- and gene-based medicine, biologics manufacturing and viral vector bioprocessing.
Current partners include Audentes, BioMarin, uniQure, AGTC, Takeda, Solid Biosciences, Lonza, Oxford Biomedica and Regeneron, as well as numerous undisclosed partners in the gene therapy and bioprocessing sectors.
FinSMEs
16/08/2019